Dietary polyphenols: Focus on resveratrol, a promising agent in the prevention of cardiovascular diseases and control of glucose homeostasis

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 8, 2010, Pages 618-625

  Borriello, A ^a   Cucciolla, V ^a   Della Ragione, F ^a   Galletti, P ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cardiovascular diseases; Glucose homeostasis; Resveratrol

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLESTEROL; GLUCOSE; RESVERATROL; STILBENE DERIVATIVE;

ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECT; HOMEOSTASIS; HUMAN; MACROPHAGE; METABOLISM; REPERFUSION INJURY; REVIEW; THROMBOCYTE AGGREGATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; GLUCOSE; HOMEOSTASIS; HUMANS; MACROPHAGES; MYOCARDIAL REPERFUSION INJURY; PLATELET AGGREGATION; STILBENES;

MUS;

EID: 77956716582     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.07.004     Document Type: Review

References (45)

1. Dixon R.A. Natural products and plant disease resistance. Nature 2001, 411:843-847.
2. Langcake P., Pryce R.J. A new class of phytoalexins from grapevines. Experentia 1977, 33:151-152.
3. Roggero J.P., Garciaparrilla C. Effects of ultraviolet irradiation on resveratrol and changes in resveratrol and various of its derivatives in the skins of ripening grapes. Sci Aliments 1995, 15:411-422.
4. Sbaghi M., Jeandet P., Faivre B., Bessis R., Fournioux J.C. Development of methods using phytoalexin (resveratrol) assessment as a selection criterion to screen grapevine in vitro cultures for resistance to grey mould (Botrytis cinerea). Euphytica 1995, 86:41-47.
5. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
6. Cucciolla V., Borriello A., Oliva A., Galletti P., Zappia V., Della Ragione F. Resveratrol: from basic science to the clinic. Cell Cycle 2007, 6:2495-2510.
7. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
8. Pezzuto J.M. Resveratrol as an inhibitor of cancerogenesis. Resveratrol in health and disease 2006, 233-383. CRC Press Taylor & Francis Group, Boca Raton. B.B. Aggarwal, S. Shishodia (Eds.).
9. Kaeberlein M., McDonagh T., Heltweg B., Hixon J., Westman E.A., Caldwell S., et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005, 280:17038-17045.
10. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005, 280:17187-17195.
11. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
12. Grønbæk M. The positive and negative health effects of alcohol- and the public health implications. J Intern Med 2009, 265:407-420.
13. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 1999, 27:160-169.
14. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 1993, 341:1103-1104.
15. Fanì E., Zhang L., Jiang S., Bai Y. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008, 11:610-614.
16. Urpí-Sardà M., Jáuregui O., Lamuela-Raventós R.M., Jaeger W., Miksits M., Covas M.I., et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005, 77:3149-3155.
17. Sevov M., Elfineh L., Cavelier L.B. Resveratrol regulates the expression of LXR-alpha in human macrophages. Biochem Biophys Res Commun 2006, 348:1047-1054.
18. Wang Z., Huang Y., Zou J., Cao K., Xu Y., Wu J.M. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002, 9:77-79.
19. Szewczuk L.M., Forti L., Stivala L.A., Penning T.M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2. J Biol Chem 2004, 279:22727-22737.
20. Shen M., Hsiao G., Liu C.L., Fong T.H., Lin K.H., Chou D.S., et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007, 139:475-485.
21. Naderali E.K., Doyle P.J., Williams G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci (London) 2000, 98:537-543.
22. Kinlay S., Libby P., Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001, 12:383-389.
23. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
24. Orallo F., Alvarez E., Camiña M., Leiro J.M., Gómez E., Fernández P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol Pharmacol 2002, 61:294-302.
25. Das S., Alagappan V.K., Bagchi D., Sharma H.S., Maulik N., Das D.K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 2005, 42:281-289.
26. Liu J.C., Chen J.J., Chan P., Cheng C.F., Cheng T.H. Inhibition of cyclic strain-induced endothelin-1 gene expression by resveratrol. Hypertension 2003, 42:1198-1205.
27. Shigematsu S., Ishida S., Hara M., Takahashi N., Yoshimatsu H., Sakata T., et al. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic Biol Med 2003, 34:810-817.
28. Ferrero M.E., Bertelli A.E., Fulgenzi A., Pellegatta F., Corsi M.M., Bonfrate M., et al. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 1998, 68:208-214.
29. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000, 164:6509-6519.
30. Lekli I., Szabo G., Juhasz B., Das S., Das M., Varga E., et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008, 294:H859-H866.
31. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007, 43:720-729.
32. Brakenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001, 15:1798-1800.
33. Csiszar A., Labinskyy N., Pinto J.T., Ballabh P., Zhang H., Losonczy G., et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009, 297:H1876-H1881.
34. Das D.K. Protective effects of resveratrol against ischemia-reperfusion. Resveratrol in health and disease 2006, 519-537. CRC Press Taylor & Francis Group, Boca Raton. B.B. Aggarwal, S. Shishodia (Eds.).
35. Hattori R., Otani H., Maulik N., Das D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 2002, 282:H1988-H1995.
36. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 alpha. Cell 2006, 127:1109-1122.
37. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
38. + metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
39. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 6:2264.
40. Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., Levine B.S. Resveratrol-associated renal toxicity. Toxicol Sci 2004, 82:614-619.
41. Almeida L., Vaz-da-Silva M., Falcao A., Soares E., Costa R., Loureiro A.I., et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009, 53:S7-S15.
42. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377-1382.
43. Soleas G.J., Yan J., Goldberg D.M. Measurement of trans-resveratrol, (1)-catechin, and quercetin in rat and human blood and urine by gas chromatography with mass selective detection. Meth Enzymol 2001, 335:130-145.
44. Soleas G.J., Yan J., Goldberg D.M. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 2001, 757:161-172.
45. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007, 16:1246-1252.